First Patient Dosed in BOL-148 Clinical Trial: Ceruvia Lifesciences Paves the Way for New Hope in Medicine

Ceruvia Lifesciences made history today, dosing the first participant in their Phase 1 clinical trial of NYPRG-101 (2-bromo-d-lysergic acid diethylamide). The pioneering trial marks an important milestone for the leading neurotransformational biopharmaceutical company, as they seek to unlock the potential of this unique compound in healthy adult participants.

Ceruvia Lifesciences is thrilled to announce the commencement of their clinical trial, starting with the dosing of the first participant, after a considerable amount of resources and time investment into the production of cGMP 2-bromo-d-lysergic acid diethylamide and completing the IND-enabling pre-clinical toxicology work. With millions of Americans and billions of people worldwide living with neurological and psychiatric disorders, there is an urgent need for safe and effective treatments. NYPRG-101 is a potential breakthrough that could provide relief from the disability and psychosocial burdens experienced by those suffering from migraine and cluster headaches.

BOL-148, also known in the literature as NYPRG-101, is an analog of LSD that has been studied extensively since the 1950s. Unlike LSD, however, it does not produce hallucinations, making it an ideal choice for clinical and experimental settings. In the decades since its discovery, research has continued to reveal more about the drug, paving the way for modern standards for clinical research.

Ceruvia’s Phase 1 clinical trial is your chance to help shape the future of healthcare! We are looking for up to 40 healthy adult participants to take part in our single ascending dose study of NYPRG-101. Your involvement will help us assess the safety, tolerability, pharmacokinetics and pharmacodynamics of this innovative treatment. Be part of something big and join us on our mission to make a difference in healthcare.

About Ceruvia Lifesciences

Ceruvia Lifesciences was founded in 2017 with the mission to revolutionize the treatment of neurological and psychiatric disorders. Led by Carey Turnbull, our team has been relentlessly focused on developing neurotransformational medicines to provide relief to patients suffering from hard-to-treat headache disorders, OCD and substance abuse disorder. Drawing on a long history of collaboration with leading researchers at Yale University School of Medicine, NYU School of Medicine and Harvard Medical School, Ceruvia is committed to delivering meaningful solutions to these underserved communities. Our aim is to help patients return to living their lives to the fullest.

Leave a Comment